Jounce Therapeutics, Inc. (NASDAQ:JNCE) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Jounce Therapeutics, Inc. (NASDAQ:JNCEGet Rating) have been assigned an average recommendation of “Moderate Buy” from the seven analysts that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $8.40.

A number of brokerages recently issued reports on JNCE. HC Wainwright dropped their price objective on Jounce Therapeutics from $15.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, August 5th. Raymond James cut Jounce Therapeutics from a “strong-buy” rating to an “outperform” rating and lowered their price target for the company from $16.00 to $3.00 in a report on Thursday, November 10th. Piper Sandler lowered their price target on Jounce Therapeutics to $6.00 in a report on Tuesday, September 6th. Robert W. Baird lowered their price target on Jounce Therapeutics to $5.00 in a report on Tuesday, August 9th. Finally, StockNews.com raised Jounce Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday.

Jounce Therapeutics Stock Performance

JNCE stock opened at $0.90 on Wednesday. The company has a market capitalization of $46.52 million, a price-to-earnings ratio of -0.35 and a beta of 1.21. Jounce Therapeutics has a fifty-two week low of $0.84 and a fifty-two week high of $8.80. The stock has a fifty day moving average of $2.08 and a 200-day moving average of $3.15.

Jounce Therapeutics (NASDAQ:JNCEGet Rating) last issued its quarterly earnings data on Thursday, November 10th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.04. Equities analysts predict that Jounce Therapeutics will post -2.3 EPS for the current year.

Hedge Funds Weigh In On Jounce Therapeutics

A number of large investors have recently modified their holdings of the company. Silverarc Capital Management LLC raised its holdings in shares of Jounce Therapeutics by 1.0% during the 1st quarter. Silverarc Capital Management LLC now owns 248,347 shares of the company’s stock valued at $1,686,000 after buying an additional 2,518 shares in the last quarter. American International Group Inc. raised its holdings in shares of Jounce Therapeutics by 20.5% during the 2nd quarter. American International Group Inc. now owns 19,722 shares of the company’s stock valued at $60,000 after buying an additional 3,355 shares in the last quarter. Fiduciary Trust Co. raised its holdings in shares of Jounce Therapeutics by 19.5% during the 1st quarter. Fiduciary Trust Co. now owns 21,185 shares of the company’s stock valued at $144,000 after buying an additional 3,463 shares in the last quarter. Amalgamated Bank purchased a new position in shares of Jounce Therapeutics during the 1st quarter valued at about $27,000. Finally, BNP Paribas Arbitrage SA raised its holdings in shares of Jounce Therapeutics by 102.9% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,115 shares of the company’s stock valued at $28,000 after buying an additional 4,623 shares in the last quarter. 86.99% of the stock is owned by hedge funds and other institutional investors.

Jounce Therapeutics Company Profile

(Get Rating)

Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors.

Featured Articles

Analyst Recommendations for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.